Which has better valuation & earnings, MNPR or NGEN?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A NervGen Pharma N/A N/A -$31.58M -$0.46 N/A

Is MNPR or NGEN more profitable?

Monopar Therapeutics' return on equity of -13.08% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% NervGen Pharma N/A -1,259.82% -199.79%

Does the media refer more to MNPR or NGEN?

In the previous week, Monopar Therapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 2 mentions for Monopar Therapeutics and 1 mentions for NervGen Pharma. Monopar Therapeutics' average media sentiment score of 0.54 beat NervGen Pharma's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or NGEN more profitable?

Shattuck Labs' return on equity of -43.57% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% NervGen Pharma N/A -1,259.82% -199.79%

Does the media refer more to STTK or NGEN?

In the previous week, Shattuck Labs had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for Shattuck Labs and 1 mentions for NervGen Pharma. Shattuck Labs' average media sentiment score of 1.15 beat NervGen Pharma's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTMX or NGEN?

In the previous week, CytomX Therapeutics had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for CytomX Therapeutics and 1 mentions for NervGen Pharma. CytomX Therapeutics' average media sentiment score of 0.72 beat NervGen Pharma's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NGEN or ALLO more profitable?

Allogene Therapeutics' return on equity of -50.04% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Allogene Therapeutics N/A -50.04% -36.74%

Does the media refer more to NGEN or ALLO?

In the previous week, Allogene Therapeutics had 9 more articles in the media than NervGen Pharma. MarketBeat recorded 10 mentions for Allogene Therapeutics and 1 mentions for NervGen Pharma. Allogene Therapeutics' average media sentiment score of 0.79 beat NervGen Pharma's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NGEN or BBOT?

NervGen Pharma is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A -$31.58M -$0.46 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is NGEN or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Does the media favor NGEN or BBOT?

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 0.00 equaled BridgeBio Oncology Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NervGen Pharma (NGEN) Competitors

$2.32 -0.01 (-0.43%)

As of 09/3/2026 04:00 PM Eastern

Compare

NGEN vs. MNPR, STTK, CTMX, ALLO, and BBOT

Should you buy NervGen Pharma stock or one of its competitors? NervGen Pharma's main competitors and comparable companies include Monopar Therapeutics (MNPR), Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Allogene Therapeutics (ALLO), and BridgeBio Oncology Therapeutics (BBOT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NervGen Pharma compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Monopar Therapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 2 mentions for Monopar Therapeutics and 1 mentions for NervGen Pharma. Monopar Therapeutics' average media sentiment score of 0.54 beat NervGen Pharma's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics presently has a consensus price target of $118.67, suggesting a potential upside of 0.10%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 503.45%. Given NervGen Pharma's higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 5.8% of NervGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Monopar Therapeutics' return on equity of -13.08% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
NervGen Pharma	N/A	-1,259.82%	-199.79%

Summary

Monopar Therapeutics beats NervGen Pharma on 9 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

NervGen Pharma has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	698.51	-$48.81M	-$0.51	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Shattuck Labs had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for Shattuck Labs and 1 mentions for NervGen Pharma. Shattuck Labs' average media sentiment score of 1.15 beat NervGen Pharma's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs' return on equity of -43.57% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
NervGen Pharma	N/A	-1,259.82%	-199.79%

Shattuck Labs currently has a consensus price target of $12.78, suggesting a potential upside of 83.59%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 503.45%. Given NervGen Pharma's higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Shattuck Labs beats NervGen Pharma on 9 of the 13 factors compared between the two stocks.

How does NervGen Pharma compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics presently has a consensus price target of $11.90, suggesting a potential upside of 223.37%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 503.45%. Given NervGen Pharma's higher probable upside, analysts clearly believe NervGen Pharma is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, CytomX Therapeutics had 5 more articles in the media than NervGen Pharma. MarketBeat recorded 6 mentions for CytomX Therapeutics and 1 mentions for NervGen Pharma. CytomX Therapeutics' average media sentiment score of 0.72 beat NervGen Pharma's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has higher revenue and earnings than NervGen Pharma. CytomX Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	10.52	-$17.37M	-$0.50	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

NervGen Pharma has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
NervGen Pharma	N/A	-1,259.82%	-199.79%

Summary

CytomX Therapeutics beats NervGen Pharma on 8 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to Allogene Therapeutics?

NervGen Pharma (NASDAQ:NGEN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

83.6% of Allogene Therapeutics shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NervGen Pharma currently has a consensus price target of $14.00, suggesting a potential upside of 503.45%. Allogene Therapeutics has a consensus price target of $8.30, suggesting a potential upside of 319.19%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe NervGen Pharma is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Allogene Therapeutics had 9 more articles in the media than NervGen Pharma. MarketBeat recorded 10 mentions for Allogene Therapeutics and 1 mentions for NervGen Pharma. Allogene Therapeutics' average media sentiment score of 0.79 beat NervGen Pharma's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics' return on equity of -50.04% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Allogene Therapeutics	N/A	-50.04%	-36.74%

NervGen Pharma has higher earnings, but lower revenue than Allogene Therapeutics. NervGen Pharma is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Allogene Therapeutics	$20K	34,203.51	-$190.89M	-$0.67	N/A

Summary

Allogene Therapeutics beats NervGen Pharma on 9 of the 14 factors compared between the two stocks.

How does NervGen Pharma compare to BridgeBio Oncology Therapeutics?

NervGen Pharma (NASDAQ:NGEN) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

NervGen Pharma is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

NervGen Pharma currently has a consensus price target of $14.00, suggesting a potential upside of 503.45%. BridgeBio Oncology Therapeutics has a consensus price target of $24.40, suggesting a potential upside of 174.16%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NervGen Pharma is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 0.00 equaled BridgeBio Oncology Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Oncology Therapeutics beats NervGen Pharma on 6 of the 11 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$187.87M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-5.04	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	15.47	16.29	12.89	6.14
Net Income	-$31.58M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.75%	0.34%	0.61%	-0.27%
1 Month Performance	39.76%	8.52%	5.73%	0.68%
1 Year Performance	N/A	52.66%	25.37%	14.84%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	1.6032 of 5 stars	$2.32 -0.4%	$14.00 +503.4%	N/A	$187.87M	N/A	N/A	N/A
MNPR Monopar Therapeutics	1.628 of 5 stars	$110.27 -3.2%	$118.67 +7.6%	+227.4%	$739.91M	N/A	N/A	10
STTK Shattuck Labs	3.8252 of 5 stars	$7.25 -5.2%	$12.78 +76.2%	+443.8%	$727.61M	$1M	N/A	100	Positive News
CTMX CytomX Therapeutics	2.5525 of 5 stars	$3.31 -3.2%	$11.90 +259.5%	+73.6%	$721.25M	$76.20M	N/A	170
ALLO Allogene Therapeutics	2.2356 of 5 stars	$2.04 -2.4%	$8.30 +306.9%	+76.8%	$704.80M	$20K	N/A	310	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. MNPR, STTK, CTMX, ALLO, and BBOT

How does NervGen Pharma compare to Monopar Therapeutics?

Summary

How does NervGen Pharma compare to Shattuck Labs?

Summary

How does NervGen Pharma compare to CytomX Therapeutics?

Summary

How does NervGen Pharma compare to Allogene Therapeutics?

Summary

How does NervGen Pharma compare to BridgeBio Oncology Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. MNPR, STTK, CTMX, ALLO, and BBOT

How does NervGen Pharma compare to Monopar Therapeutics?

Does the media refer more to MNPR or NGEN?

Do analysts prefer MNPR or NGEN?

Which has better valuation & earnings, MNPR or NGEN?

Do insiders and institutionals hold more shares of MNPR or NGEN?

Is MNPR or NGEN more profitable?

Summary

How does NervGen Pharma compare to Shattuck Labs?

Which has higher earnings & valuation, STTK or NGEN?

Do institutionals and insiders hold more shares of STTK or NGEN?

Does the media refer more to STTK or NGEN?

Is STTK or NGEN more profitable?

Do analysts recommend STTK or NGEN?

Summary

How does NervGen Pharma compare to CytomX Therapeutics?

Do insiders & institutionals hold more shares of CTMX or NGEN?

Do analysts prefer CTMX or NGEN?

Does the media refer more to CTMX or NGEN?

Which has stronger earnings & valuation, CTMX or NGEN?

Is CTMX or NGEN more profitable?

Summary

How does NervGen Pharma compare to Allogene Therapeutics?

Do insiders and institutionals believe in NGEN or ALLO?

Do analysts prefer NGEN or ALLO?

Does the media refer more to NGEN or ALLO?

Is NGEN or ALLO more profitable?

Which has stronger valuation and earnings, NGEN or ALLO?

Summary

How does NervGen Pharma compare to BridgeBio Oncology Therapeutics?

Is NGEN or BBOT more profitable?

Which has higher earnings and valuation, NGEN or BBOT?

Do analysts recommend NGEN or BBOT?

Do insiders and institutionals hold more shares of NGEN or BBOT?

Does the media favor NGEN or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools